Galectin Therapeutics
GALT
77 hedge funds and large institutions have $19M invested in Galectin Therapeutics in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 8 closing their positions.
54% more call options, than puts
Call options by funds: $321K | Put options by funds: $208K
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
0.71% less ownership
Funds ownership: 17.69% → 16.98% (-0.71%)
1% less funds holding
Funds holding: 78 → 77 (-1)
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
34% less capital invested
Capital invested by funds: $28.8M → $19M (-$9.81M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$98.6K |
| 2 |
JP Morgan Chase
New York
|
+$66.8K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$65K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$55.4K |
| 5 |
Two Sigma Investments
New York
|
+$41.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$263K |
| 2 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
-$255K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$219K |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$174K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$122K |
GALT Hedge Fund Activity: Q1 2020 in Review
77 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2020, worth a combined $19M — down 34% from $28.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GALT positions and 8 closed out — a net gain of 2 holders — while 17 added to existing stakes and 21 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $98.6K. The largest seller was Morgan Stanley, cutting an estimated $263K.
- 77 institutional investors held Galectin Therapeutics (GALT) as of Q1 2020, down from 78 in Q4 2019.
- Funds reported $19M of Galectin Therapeutics stock for Q1 2020, down 34% quarter-over-quarter.
- 10 funds opened new Galectin Therapeutics positions in Q1 2020 and 8 closed out, a net change of +2 holders.
- The largest Galectin Therapeutics buyer in Q1 2020 was Citadel Advisors, an estimated $98.6K added.
- The largest Galectin Therapeutics seller in Q1 2020 was Morgan Stanley, an estimated $263K sold.
Based on aggregated 13F filings for Q1 2020.